The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials

BackgroundPrevious studies revealed that Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents had extensive anti-tumor activities. However, almost all studies on the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angioge...

Full description

Bibliographic Details
Main Authors: Shubin Chen, Wanying Mo, Wei Jiang, Shaozhang Zhou, Haijie Gan, Qitao Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
advanced non-small cell lung cancer
second or later-line therapy
PD-1/PD-L1 inhibitors
anti-angiogenic agents
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1218258/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1218258/full

Similar Items